Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2025-08-19 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民药业集团股份有限公司制度文件（20250819）
Governance Information Classification · 95% confidence The document is a detailed internal control system and management policy document for a company, including internal control principles, risk assessment, control activities, information disclosure, and management of senior executives' compensation. It references regulatory frameworks such as the Company Law of the People's Republic of China, Securities Law, and Shanghai Stock Exchange listing rules. The content is focused on governance, internal control, risk management, and remuneration policies for senior management. It does not contain financial statements or earnings data, nor is it a transcript, announcement, or presentation. It is a governance-related document detailing internal rules and practices, including remuneration management. Therefore, the document fits best under Governance Information (CGR) for the internal control system and Remuneration Information (DEF 14A) for the senior management compensation policies. Since the document includes both internal control system and remuneration policies, but the majority and main body is about internal control and governance, the primary classification is Governance Information (CGR). Confidence is high due to the detailed governance and internal control content and the presence of remuneration policies as part of governance.
2025-08-19 Chinese
健民集团2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2025 年半年度报告摘要" which translates to "2025 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including total assets, net assets, revenue, profit, earnings per share, and explanations of accounting data. It also includes shareholder information and other company details. The document explicitly states it is a summary of the half-year report and advises investors to read the full report on the official exchange website. The document length is 2789 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. It is not a mere announcement or certification but contains actual financial figures and explanations. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-19 Chinese
健民集团第十一届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company '健民药业集团股份有限公司' dated August 20, 2025. It reports on the approval of the 2025 semi-annual report and revisions to corporate governance-related systems. The text references the actual semi-annual report being disclosed elsewhere (on stock exchange websites and newspapers), indicating this document is not the report itself but an announcement of board decisions and approvals. It also includes governance-related decisions but primarily serves as a formal announcement of board resolutions rather than detailed governance documentation. The document length is short (805 characters), consistent with an announcement rather than a full report. Therefore, the best classification is 'Board/Management Information' (MANG), as it announces board meeting resolutions and decisions.
2025-08-19 Chinese
健民集团2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "健民药业集团股份有限公司2025 年半年度报告" which translates to "Jianmin Pharmaceutical Group Co., Ltd. 2025 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company business overview, industry and policy environment, and other comprehensive information typical of a half-year financial report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes sections such as "管理层讨论与分析" (Management Discussion and Analysis), financial data tables, and detailed narrative on business operations and risks. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-19 Chinese
健民集团关于获得《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving an official approval notice for clinical drug trials from the National Medical Products Administration. It details the drug's basic information, clinical trial approval, market context, and regulatory steps ahead. The document is short (1575 characters) and serves as a formal disclosure of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval notice. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-08-14 Chinese
健民集团关于召开2025年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2025 half-year performance explanation meeting (业绩说明会) for investors. It specifies the date, time, location, participants, and how investors can participate and ask questions. It mentions that the company's 2025 half-year report will be published on August 20, 2025, but this document itself is not the report or the financial data. It is a notice about an upcoming investor presentation event focused on discussing the half-year results. The document length is short (1524 characters), and it does not contain financial statements or detailed analysis, only information about the meeting. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the actual report or earnings release.
2025-08-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.